Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data / 한국유방암학회지
Journal of Breast Cancer
;
: 415-424, 2018.
Article
in English
| WPRIM
| ID: wpr-718891
ABSTRACT
PURPOSE:
Triple-positive breast cancer is defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) positivity. Several systemic breast cancer therapies target hormonal and HER2 responsiveness. We compared clinical outcomes of triple-positive disease with those of HER2-enriched and luminal HER2-negative disease and investigated the clinical efficacy of anti-HER2 therapy for triple-positive disease.METHODS:
We retrospectively compared overall and recurrence-free survival among cases included in the Korean Breast Cancer Society (KBCS) and Seoul St. Mary's Hospital breast cancer registries and the therapeutic efficacy of trastuzumab for triple-positive and HER2-enriched cases.RESULTS:
KBCS registry data (2006–2010; median follow-up, 76 months) indicated that patients with triple-positive breast cancer had intermediate survival between those with luminal A and HER2-enriched subtypes (p < 0.001). Trastuzumab did not improve overall survival among patients with triple-positive breast cancer (p=0.899) in contrast to the HER2-enriched subtype (p=0.018). Seoul St. Mary's Hospital registry data indicated similar recurrence-free survival outcomes (p < 0.001) and a lack of improvement with trastuzumab among patients with triple-positive breast cancer (median follow-up, 33 months; p=0.800). Multivariate analysis revealed that patients with triple-positive breast cancer had better overall survival than those with HER2-enriched disease and similar survival as those with the luminal A subtype (triple-positive hazard ratio, 1.258, p=0.118; HER2-enriched hazard ratio, 2.377, p < 0.001).CONCLUSION:
Our findings showed that anti-HER2 therapy was less beneficial for treatment of triple-positive breast cancer than for HER2-enriched subtypes of breast cancer, and the triple-positive subtype had a distinct prognosis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phenobarbital
/
Prognosis
/
Breast
/
Breast Neoplasms
/
Receptors, Progesterone
/
Receptors, Estrogen
/
Registries
/
Multivariate Analysis
/
Retrospective Studies
/
Follow-Up Studies
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Breast Cancer
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS